Business Context and Reporting Period
This Form 6-K filing by Hebron Technology Co., Ltd. (not AIOS Tech Inc.) covers the month of March 2018. The report discloses a material corporate transaction entered into on March 10, 2018, involving the acquisition of a minority stake in a Chinese bio-technology firm.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a specific equity acquisition.
- Target Company: Xuzhou Weijia Bio-Tech Co., Ltd. ("Weijia Bio-Tech")
- Acquisition Stake: 49% equity interest
- Valuation of Target: RMB 37.1 million
- Transaction Value: RMB 18.18 million (49% interest)
- Consideration: Issuance of 1,442,778 unregistered Class A common shares
- Agreed Share Price: $2.00 per share
Material Changes
The primary material change is the expansion of Hebron Technology's business portfolio through the acquisition of Weijia Bio-Tech. This transaction results in the issuance of new unregistered shares, which will dilute existing shareholders. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, earnings outlook, or management commentary regarding future financial performance. Key contingencies and terms include:
- Share Issuance Timeline: Shares must be issued within 20 business days of signing the agreement.
- Lock-up Restrictions:
- 448,000 Class A shares are restricted for one year.
- 100,000 Class A shares are restricted for six months.
- Transfer Prohibition: Restricted shares cannot be sold, gifted, pledged, or transferred during the lock-up period.
Investor Verification Checklist
- Verify the exact number of outstanding shares prior to this issuance to calculate the dilution impact of the 1,442,778 new shares.
- Confirm the current market price of Hebron Technology's Class A shares to assess the premium or discount relative to the $2.00 agreed transaction price.
- Review the full Share Acquisition Agreement (Exhibit 10.1) for conditions precedent to closing and representations made by Weijia Bio-Tech.
- Investigate the financial health and regulatory standing of Xuzhou Weijia Bio-Tech Co., Ltd. as the filing provides no audited financials for the target.